Feed TAK
TA

Takeda TAK NYSE · Healthcare · Japan

$21.80 +1.80% +$0.39

Summary

50 / 100 · Bulios Score

What speaks for it

  • The price moves less than the market (beta 0.09).

What to watch

  • The share price is above the Bulios Fair Price.
  • Operating profit covers the interest on its debt only 2.3 times.
  • It earns only 4.8 JPY a year on every 100 JPY of invested capital.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks expensive
Bulios Fair Price
Overvalued Price today $21.8

By our assumptions the business is worth less than its shares cost today.

P/E today 28.3 28% lower
5-year average P/E 39.5
P/E today 28.3
Drug Manufacturers - Specialty & Generic industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 28.3 JPY for 1 JPY of yearly profit. Over the last five years it was 39.5 JPY on average.

Valuation in detail

Is it growing?

Slowly

Revenue (JPY)

Diluted EPS (JPY)

  • Analyst estimate

Revenue grew by 7.1% a year over 5 years. Over the last 3 years it grew by 3.8% a year. For the next fiscal year analysts expect revenue to grow by 4.6%.

Growth in detail

Does it make money?

Very well

Where 100 JPY of revenue goes

Net profit, industry median (Drug Manufacturers - Specialty & Generic) 9.9 JPY

Out of every 100 JPY of revenue, 8.2 JPY is left as net profit.

Profitability in detail

Is it financially healthy?

Debt is a burden

Repaying all its debt would take 10.2 years of free cash flow. Its debt is larger than its cash.

Financial health in detail

Does it pay a dividend?

Moderate, stretched
Yield
2.90%
Paid out of profit
82%
Raised in a row
1 year

You receive $0.62 per share a year. The payout takes a large part of its profit or free cash flow.

Dividends in detail

What do analysts expect?

Mildly positive

No analyst has published a price target.

83% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2025

By product

By region

Gastroenterology brings in 31% of revenue. PDT Immunology grew fastest, by 20% a year.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy